Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Apixaban and rivaroxaban are leading oral anticoagulants for acute venous thromboembolism (VTE).
• Clinical data comparing the bleeding risk between apixaban and rivaroxaban in VTE patients remains limited.
• Understanding differential bleeding profiles is crucial for optimizing VTE treatment strategies.

Purpose of the Study:

• To directly compare the incidence of clinically relevant bleeding between apixaban and rivaroxaban in patients with acute VTE.
• To evaluate secondary outcomes, including all-cause mortality, in patients treated with either anticoagulant.

Main Methods:

• An international, prospective, randomized, open-label, blinded end-point trial involving 2760 patients with acute pulmonary embolism or deep-vein thrombosis.
• Patients received either apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) or rivaroxaban (15 mg twice daily for 21 days, then 20 mg daily) for 3 months.
• The primary endpoint was a composite of major or clinically relevant nonmajor bleeding, assessed using International Society on Thrombosis and Haemostasis criteria.

Main Results:

• A primary outcome event occurred in 3.3% of the apixaban group versus 7.1% of the rivaroxaban group (Relative Risk: 0.46; 95% CI, 0.33-0.65; P<0.001).
• All-cause mortality was low in both groups (0.1% for apixaban vs. 0.3% for rivaroxaban).
• Serious adverse events unrelated to bleeding or thrombosis were comparable between groups.

Conclusions:

• Apixaban demonstrated a significantly lower risk of clinically relevant bleeding compared to rivaroxaban in patients treated for acute venous thromboembolism over a 3-month period.
• The findings suggest apixaban may offer a superior safety profile regarding bleeding complications in this patient population.
• Further research may explore long-term outcomes and specific patient subgroups.